Evidence map›Paper›PMID 40169258›Full record

ArticleLife science alliance2025

The RBR E3 ubiquitin ligase HOIL-1 can ubiquitinate diverse non-protein substrates in vitro.

Xiangyi S Wang, Jenny Jiou, Anthony Cerra, Simon A Cobbold, Marco Jochem, Ka Hin Toby Mak, Leo Corcilius, John Silke, Richard J Payne, Ethan D Goddard-Borger and 2 more

Abstract read
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. E2 variants for probing E3 ubiquitin ligase activities.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiangyi S WangUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-1235-6616
Jenny JiouUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-2124-5272
Anthony CerraUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0009-0002-8023-6445
Simon A CobboldUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Marco JochemUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Ka Hin Toby MakSchool of Chemistry, The University of Sydney, Sydney, Australia.
Leo CorciliusSchool of Chemistry, The University of Sydney, Sydney, Australia.ORCID 0009-0003-0155-3619
John SilkeDepartment of Medical Biology, The University of Melbourne, Parkville, Australia.ORCID 0000-0002-7611-5774
Richard J PayneSchool of Chemistry, The University of Sydney, Sydney, Australia.
Ethan D Goddard-BorgerDepartment of Medical Biology, The University of Melbourne, Parkville, Australia.
David KomanderUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-8092-4320
Bernhard C LechtenbergUbiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia lechtenberg.b@wehi.edu.au.ORCID 0000-0002-5674-6894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HOIL-1 is a RING-between-RING-family E3 ubiquitin ligase and a component of the linear ubiquitin chain assembly complex. Although most E3 ubiquitin ligases conjugate ubiquitin to protein lysine sidechains, HOIL-1 has also been reported to ubiquitinate hydroxyl groups in protein serine and threonine sidechains and glucosaccharides, such as glycogen and its building block maltose, in vitro. However, HOIL-1 substrate specificity is currently poorly defined. Here, we show that HOIL-1 is unable to ubiquitinate lysine but can efficiently ubiquitinate serine and a variety of model and physiologically relevant di- and monosaccharides in vitro. We identify a critical catalytic histidine residue, His510, in the flexible catalytic site of HOIL-1 that enables this O-linked ubiquitination and prohibits ubiquitin discharge onto lysine sidechains. We use HOIL-1's in vitro non-proteinaceous ubiquitination activity to produce preparative amounts of different ubiquitinated saccharides that can be used as tool compounds and standards in the rapidly emerging field of non-proteinaceous ubiquitination. Finally, we report an engineered, constitutively active HOIL-1 variant that simplifies in vitro generation of ubiquitinated saccharides.

Indexed as

Ubiquitin-Protein LigasesCatalytic DomainHistidineHumansLysineSerineSubstrate SpecificityUbiquitinUbiquitinationHistidineLysineRNF31 protein, humanSerineUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID40169258
PMCPMC11962058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.